Description: Tandem’s Control‑IQ is an advanced hybrid closed‑loop algorithm integrated into their t:slim X2 (and Mobi) insulin pumps that uses CGM data to predict glucose levels 30 minutes ahead and automatically adjusts insulin delivery every 5 minutes.  It modulates basal rates—raising them if a high is anticipated and suspending insulin if a low is imminent—and can deliver automatic correction boluses up to once per hour when glucose is predicted above about 180 mg/dL. Control‑IQ offers specialized modes like Sleep (target ~112.5–120 mg/dL) and Exercise (target ~140–160 mg/dL) to reduce risks during vulnerable periods. It's FDA‑approved for individuals as young as 6 (and Control‑IQ+ now covers ages 2+) and has been shown to significantly increase time in range and lower A1C levels. Users still manually bolus for meals, but the system’s auto‑correction and predictive adjustments ease overall glucose management.

Treatment For:

Diabetes, Type 1

AI generated Summary: Based on the provided information, there are no user reviews available for the treatment "Tandem Control-IQ" for Type 1 Diabetes. Without any user feedback or author review and rating, it is not possible to determine the effectiveness of this treatment from the given data.